Physician profile
Deepanshu Garg
NPI 1649377813
$13,220.11
in general payments reported to CMS, 2019-2025
64 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,146 · 2020: $2,031 · 2021: $2,303 · 2022: $2,101 · 2023: $1,375 · 2024: $1,896 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,638.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,817.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,542.74 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,466.96 | 2019-2024 | Breztri, Farxiga |
| Pfizer INC. | $863.54 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $838.23 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbott Laboratories | $598.31 | 2019-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Janssen Pharmaceuticals, INC | $527.37 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $474.33 | 2019-2025 | Veozah |
| Abbvie INC. | $473.77 | 2019-2025 | |
| Lilly USA, LLC | $448.99 | 2020-2025 | Mounjaro, Trulicity, Jardiance |
| Boston Scientific Corporation | $373.47 | 2019-2025 | Axonics, Bodyguardian, Watchman Flx |
| Sanofi-Aventis U.S. LLC | $263.27 | 2019-2025 | |
| Medtronic, INC. | $222.60 | 2021-2025 | Intellis Adaptivestim, Symplicity G3, Minimed 780g |
| E.R. Squibb & Sons, L.L.C. | $222.49 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $205.29 | 2019-2025 | Capvaxive, Gardasil 9 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepanshu Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.